{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-088141","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.142563+00:00","generated_at":"2026-05-15T22:12:56.184961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunome reports FY2025 net loss $212.4M; cash $653.5M; varegacestat NDA planned Q2 2026","bullets":["Cash and equivalents $653.5M as of Dec 31, 2025; runway expected into 2028.","Net loss of $212.4M for FY2025; R&D expenses $177.3M.","Phase 3 RINGSIDE met primary endpoint: 84% reduction in risk of progression or death (HR=0.16, p<0.0001).","NDA submission for varegacestat in desmoid tumors planned for Q2 2026.","Three IND submissions for solid tumor ADCs (IM-1617, IM-1340, IM-1335) planned in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-088141","json":"https://secwatch.observer/filing/0001193125-26-088141.json","markdown":"https://secwatch.observer/filing/0001193125-26-088141.md","text":"https://secwatch.observer/filing/0001193125-26-088141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/0001193125-26-088141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:12:56.184961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}